In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Aurinia Pharmaceuticals Inc’s stock clocked out at $8.11, down -0.49% from its previous closing price of $8.15. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 2.9 million shares were traded. AUPH stock price reached its highest trading level at $8.33 during the session, while it also had its lowest trading level at $8.0753.
Ratios:
To gain a deeper understanding of AUPH’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.78. For the most recent quarter (mrq), Quick Ratio is recorded 4.17 and its Current Ratio is at 4.57. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.17.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 07 ’25 when Keenan Greg sold 8,305 shares for $8.23 per share. The transaction valued at 68,350 led to the insider holds 153,484 shares of the business.
Greenleaf Peter sold 195,593 shares of AUPH for $1,564,744 on Mar 03 ’25. The Chief Executive Officer now owns 1,953,892 shares after completing the transaction at $8.00 per share. On Mar 04 ’25, another insider, Greenleaf Peter, who serves as the Chief Executive Officer of the company, sold 164,947 shares for $7.92 each. As a result, the insider received 1,306,380 and left with 1,788,945 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1113819264 and an Enterprise Value of 834749440. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 210.10, and their Forward P/E ratio for the next fiscal year is 10.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.74 while its Price-to-Book (P/B) ratio in mrq is 3.03. Its current Enterprise Value per Revenue stands at 3.55 whereas that against EBITDA is 19.074.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.20, which has changed by 0.5686654 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $10.67, while it has fallen to a 52-week low of $4.71. The 50-Day Moving Average of the stock is 0.42%, while the 200-Day Moving Average is calculated to be 13.00%.
Shares Statistics:
It appears that AUPH traded 1.42M shares on average per day over the past three months and 2202540 shares per day over the past ten days. A total of 140.88M shares are outstanding, with a floating share count of 122.12M. Insiders hold about 11.08% of the company’s shares, while institutions hold 42.23% stake in the company. Shares short for AUPH as of 1740700800 were 11507862 with a Short Ratio of 8.13, compared to 1738281600 on 9392276. Therefore, it implies a Short% of Shares Outstanding of 11507862 and a Short% of Float of 8.430000399999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
